ZILUCOPLAN

Brand name:

• Zilbrysq®

Pharmaceutical company:

UCB AUSTRALIA PROPRIETARY LIMITED

Condition/indication:
(therapeutic use)

• Generalised myasthenia gravis (gMG)

PBAC Submission type:

New PBS listing (Category 1)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – July 2024

Related medicines:

--

Submission received for:

July 2024 PBAC meeting

Opportunity for consumer comment:

Open 03/04/2024 and close 29/05/2024 (see PBS Website)

PBAC meeting:

Held on 10/07/2024

PBAC outcome published:

Not Recommended (see PBAC Outcomes)

5Lodgement of required documentation:

Has not yet commenced

6Agreement to listing arrangements:

Has not yet commenced

7Government processes:

Has not yet commenced

8Medicine listed on the PBS:

Has not yet occurred

---